MARC JOHNSON: Open Payments
NPI 1700620622 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,110 in 112 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $174 · 2025 $2,110
Food & beverage: $2,110
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $587 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $338 |
| Axsome Therapeutics, Inc. | 7 | $241 |
| Otsuka America Pharmaceutical, Inc. | 13 | $176 |
| JAZZ PHARMACEUTICALS INC. | 9 | $153 |
| Neurocrine BioSciences, Inc. | 12 | $149 |
| HARMONY BIOSCIENCES LLC | 3 | $79 |
| Janssen Pharmaceuticals, Inc | 4 | $76 |
| E.R. Squibb & Sons, L.L.C. | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
Products named: VRAYLAR, CAPLYTA, Auvelity, XYWAV, INGREZZA, REXULTI, WAKIX, ABILIFY MAINTENA.
Industry payments across NE — which companies pay providers there.
